Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 226,812
  • Shares Outstanding, K 37,614
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -50,160 K
  • 60-Month Beta -0.85
  • Price/Sales 211.01
  • Price/Cash Flow N/A
  • Price/Book 1.15
Trade TERN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.46
  • Low Estimate -0.49
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +16.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.38 +37.67%
on 11/16/22
7.73 -21.99%
on 11/03/22
-0.88 (-12.74%)
since 10/25/22
3-Month
3.57 +68.91%
on 09/06/22
7.73 -21.99%
on 11/03/22
+1.62 (+36.73%)
since 08/25/22
52-Week
1.45 +315.86%
on 05/20/22
7.92 -23.86%
on 12/02/21
-1.50 (-19.92%)
since 11/24/21

Most Recent Stories

More News
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE

Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE have been highlighted in this Screen of The Week article.

AB : 41.11 (+0.44%)
ALE : 66.93 (+1.61%)
TERN : 6.03 (+7.49%)
3 Stocks for Higher Returns as New Analysts Initiate Coverage

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), AllianceBernstein (AB) and ALLETE (ALE).

AB : 41.11 (+0.44%)
ALE : 66.93 (+1.61%)
TERN : 6.03 (+7.49%)
Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO

Terns Pharmaceuticals, Napco Security Technologies and AVEO have been highlighted in this Screen of The Week article.

AVEO : 14.87 (+0.07%)
NSSC : 26.45 (+0.88%)
TERN : 6.03 (+7.49%)
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), Napco Security (NSSC) and AVEO.

AVEO : 14.87 (+0.07%)
NSSC : 26.45 (+0.88%)
TERN : 6.03 (+7.49%)
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

TERN : 6.03 (+7.49%)
All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy

Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TERN : 6.03 (+7.49%)
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant...

TERN : 6.03 (+7.49%)
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

TERN : 6.03 (+7.49%)
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development FOSTER CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Terns...

TERN : 6.03 (+7.49%)
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data...

TERN : 6.03 (+7.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY,...

See More

Key Turning Points

3rd Resistance Point 6.71
2nd Resistance Point 6.42
1st Resistance Point 6.23
Last Price 6.03
1st Support Level 5.75
2nd Support Level 5.46
3rd Support Level 5.27

See More

52-Week High 7.92
Last Price 6.03
Fibonacci 61.8% 5.45
Fibonacci 50% 4.68
Fibonacci 38.2% 3.92
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar